Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
Showing 661–720 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
…an tumor patient samples representing a variety of indications. INDUCER™ molecules that target tumor-associated antigens exhibited potent cytotoxi…
… PD-L1, resulting in robust proinflammatory cytokine secretion. PD-L1 ISACs utilizing Fc-attenuated antibodies elicited weaker responses fr…
…ll tolerated, being the main clinical indication of insomnia. A melatonin agonist is approved as an antidepressant. Thus, the objective o…
… mg LNG) doses in the conception cycle. Two studies of repeated ulipristal acetate (UPA) use provided very low certainty evidence. One non-compara…
…hromycin vs discontinuation trial in COPD patients on long-term azithromycin prophylaxis to reduce exacerbations. We performed a trial sub-s…
…atients started the deprescribing pathway. So far, 100% (n= 11) theophylline, 98% (n= 45) montelukast, 82% (n= 49) LAMA inhalers, 85% (n= 13…
…ne visual analogue scale [VAS] score ≥55 mm), the TRPM8 agonist AX-8 reduced bout frequency (cough bouts are defined as clusters of …
…or as first line for M. Abscessus. Ten (29%) centres prescribed Bedaquiline for NTM-PD. Treatment duration varied between 3–6 months (n=7,7…
…ent staining and western blotting. Cells were also treated with TGF-β1 (5ng/ml) for 1, 3, and 5 days. Transcript levels of α-SMA, e-ca…
…l interaction P values for data presented were >0.05.Conclusion Dupilumab reduced moderate or severe exacerbation rates, and improved lun…
…crease (~8%) in methylation between baseline and 3 months among Mepolizumab responders, while non-responders exhibited an increase (~4%). A…
…ling of the airways, typically resistant to standard therapies. Mepolizumab, an anti-IL-5 biologic, reduces eosinophil levels and improves …